Investing.com - Financial Markets Worldwide
June's AI-picked stock updates now live. See what's new in Tech Titans, up 28.5% year to date.Unlock Stocks

Afreximbank approves $2 bln for African nations to secure COVID-19 vaccines

Published 23/02/2021, 15:32
© Reuters
AZN
-

ABUJA, Feb 23 (Reuters) - The African Export-Import Bank
(Afrexim) has approved $2 billion to support the acquisition of
COVID-19 vaccines for African countries, its president said on
Tuesday.
The African Union initially secured 270 million COVID-19
vaccine doses from manufacturers for member states. In January,
it was announced that the bloc would receive another 400 million
doses of the AstraZeneca (NASDAQ:AZN) vaccine.
President Benedict Oramah told CNBC Africa Television the
Afrexim board has approved the funds and that it was seeking to
raise more funds for vaccine acquisition.
He said that the 270 million doses will only cover around
15% of Africa's population, far short of the 40% to 60% needed
for immunity.
Africa's reported COVID-19 death toll surpassed 100,000 last
week, a fraction of that reported on other continents but rising
fast as a second wave of infections overwhelms
hospitals. Faisal Shuaib, who heads Nigeria's National Primary Health
Care Development Agency, has said the country was "exploring
multiple payment options" for the doses including through an
Afrexim financing plan to make repayments in installments over
five to seven years.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.